首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1419145

疫苗市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按類型、技術、應用、給藥途徑、年齡、最終用戶（和地理位置）

Vaccines Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Technology, Application, Route of Administration, Age, End User,(and Geography)

出版日期: 2023年11月30日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

疫苗市場預計將從2022年的1,352.8億美元成長到2030年的2,163.0億美元；預計 2022 年至 2030 年複合CAGR為 6.0%。傳染病流行率上升以及 COVID-19 大流行期間疫苗使用量的增加是推動疫苗市場成長的幾個因素。

疫苗是一種生物製劑，可提供針對特定傳染病或惡性疾病的主動獲得性免疫力。疫苗製劑通常含有與致病微生物相似的試劑，通常由微生物、毒素或其表面蛋白之一的弱化或去活化形式製成。疫苗可以是預防性的，也可以是治療性的，可以提供免疫力。

市場機會

治療性疫苗開發

傳統疫苗刺激針對病毒和細菌等特定病原體的抗體和免疫蛋白質的產生。同樣，治療性疫苗會刺激免疫系統瞄準癌細胞並控制愛滋病毒等慢性感染的進展。此外，治療性疫苗通常會刺激接受者的免疫系統以減緩或阻止慢性疾病進展或針對癌細胞。此外，用於治療非傳染性疾病的治療性疫苗涵蓋多種可能的製劑、抗原和作用機制。因此，治療性疫苗的開發將為2022-2030年的預測期間提供利潤豐厚的市場機會。

正在開發的治療性疫苗的例子

適應症開發階段

卵巢癌第一期

多發性骨髓瘤第一期

1 型糖尿病臨床前

急性骨髓性白血病3

間皮瘤2

資料來源：TheInsight Partners 分析

市場洞察

傳染病不斷增加

根據康乃狄克州公共衛生部 2020 年報告，以下是康乃狄克州 2020 年記錄的傳染病。

2020 年康乃狄克州通報疾病通報病例

疾病總數

甲型肝炎 15

98 型流感

瘧疾4

結核病 54

SARS-CoV-2 2,00,379

資料來源：TheInsight Partners 分析

此外，下表顯示衛生防護中心報告2020年值得注意的傳染病：

值得注意的傳染病

疾病總數

SARS-CoV-2 8847

水痘 1987

社區相關的抗甲氧西林金黃色葡萄球菌感染 813

登革熱 22

結核病 3656

資料來源：TheInsight Partners 分析

在所有傳染病中，SARS-CoV-2 在 2020 年至 2022 年期間一直處於高位，而登革熱、水痘、結核病等其他疫苗的使用率卻較低。然而，由於全球病例不斷增加，SARS-CoV-2 疫苗的使用率一直很高。根據 2021 年發布的英國公共衛生報告，英國 12 個月的 DTaP/IPV/Hib/HepB3 疫苗接種覆蓋率增加了 0.1% 至 92.2%，輪狀病毒疫苗接種率增加了 0.3% 至 90.6%。而MenB2較上年下降0.1%，佔92.3%。此外，英國 NHS 報告顯示，2022 年 12 月，所有成人護理院居民中共有 88.9 人接種了 COVID-19 加強劑疫苗。因此，傳染病盛行率上升，疫苗接種需求很高，導致 2022-2030 年預測期內整體市場成長。

基於類型的見解

根據類型，疫苗市場分為減毒活疫苗、去活化疫苗、類毒素疫苗、次單位和結合疫苗等。減毒活疫苗細分市場在 2022 年佔據最大的市場佔有率。減毒活疫苗是用於預防多種疾病的非常有效的疫苗，包括流感、水痘、麻疹、小兒麻痺和結核病。根據世界衛生組織 (WHO) 的報告，全球約有 10 億例季節性流感病例，其中 500 萬例重症病例。此外，它每年導致約 29 萬至 65 萬人因呼吸系統死亡。因此，減毒活流感疫苗（LAIV）被證明有利於對抗人群中的感染。例如，LAIV 可為 65 歲以下的成年人提供高達 90% 的保護，為 65 歲以上的成年人提供高達 40% 的保護。上述因素對 2022-2030 年預測期間的細分市場成長有影響。

根據應用，疫苗市場分為人類乳突病毒 (HPV)、癌症、MMR、DPT 等。 2022 年，HPV 細分市場佔據最大的市場佔有率。根據WHO 報告，HPV 在撒哈拉以南非洲地區的女性中高度流行（24%），其次是拉丁美洲和加勒比地區（16%）、東歐（14% ））和東南亞（14%）。此外，全球每年有 625,600 名女性和 694,000 名男性患有 HPV 相關癌症。此外，到 2020 年，子宮頸癌佔女性 HPV 相關癌症的 93%。因此，由於盛行率上升，人們對 HPV 疫苗的需求很高，因為這些疫苗可以預防尖圭濕疣和大多數子宮頸癌。此外，HPV疫苗得到了美國食品藥物管理局（USFDA）的高度認可。「GARDASIL 9」就是美國 FDA 核准的 HPV 疫苗的一個例子。上述因素對 2022-2030 年預測期間的細分市場成長具有影響力。

基於管理的洞察之路

從給藥途徑來看，疫苗市場分為口服、鼻腔和注射。注射劑細分市場在 2022 年將佔據更大的市場佔有率。最常見的疫苗接種途徑是注射途徑，因為透過皮下或皮內途徑注射疫苗可能會導致局部刺激、皮膚變色、發炎等。

此外，CDC 報告顯示 DTaP、DT、HepA、HepB、Hib、HPV、IIV4、RIV4、ccIIV4、IPV*†、MenACWY、MenB、MMR‡、PCV13、PPSV23*†、RZV、Td、Tdap、TT、 VAR†是經由注射給藥途徑施用的常見疫苗。透過注射途徑注射的各種疫苗是影響 2022-2030 年預測期間細分市場成長的獨立因素。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 14 章：Covid-19 前後的影響

第 15 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第16章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 17 章：疫苗市場 - 主要公司概況

注意 - 將為以下公司列表提供類似資訊

輝瑞公司
賽諾菲
默克
印度血清研究所 (SII)
阿斯利康
生物科技
生物E
科興
國藥控股
巴拉特生物技術公司

第 18 章：附錄

詞彙表
關於 Insight Partners
市場情報雲

簡介目錄

Product Code: TIPRE00015468

The vaccines market is expected to grow from US$ 135.28 billion in 2022 to US$ 216.30 billion by 2030; it is expected to grow at a CAGR of 6.0% from 2022 to 2030. Rising prevalence of infectious diseases and an increase for uptake of vaccines amid the COVID-19 pandemic are a few factors driving the vaccines market growth.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. A vaccine typically preparation contains an agent responsible for resembling a disease-causing microorganism and is often made from a weakened or killed form of the microbe, toxin, or one of its surface proteins. Vaccines can be prophylactic or therapeutic, offering immunity.

Market Opportunity

Therapeutic Vaccine Development

Traditional vaccines stimulate the production of antibodies and immune proteins that target specific pathogens like viruses and bacteria. Likewise, therapeutic vaccines stimulate the immune system to target cancer cells and control the progression of chronic infections like HIV. Further, therapeutic vaccines typically stimulate the recipient's immune system to slow or stop chronic disease progression or target cancer cells. Further, therapeutic vaccines for the treatment of noninfectious diseases encompass a wide variety of possible formulations, antigens, and mechanism of action. Therefore, therapeutic vaccines development will provide lucrative market opportunity for the forecast period 2022-2030.

Examples of Therapeutic Vaccines in Development

Indication Development Phase

Ovarian Cancer Phase 1

Multiple Myeloma Phase 1

Type 1 Diabetes Preclinical

Acute Myelogenous Leukemia 3

Mesothelioma 2

Source: TheInsight Partners Analysis

Market Insights

Rising Infectious Diseases

According to the Connecticut Department of Public Health report 2020, below are the infectious diseases recorded in 2020 in Connecticut.

Reported Cases of Connecticut Reportable Diseases in 2020

Disease Total

Hepatitis A 15

Influenza 98

Malaria 4

Tuberculosis 54

SARS-CoV-2 2,00,379

Source: TheInsight Partners Analysis

Additionally, the below table reveals notable infectious disease by the Center for Health Protection report in 2020:

Notable Infectious Disease

Disease Total

SARS-CoV-2 8847

Chickenpox 1987

Community-associated methicillin-resistant Staphylococcus aureus infection 813

Dengue Fever 22

Tuberculosis 3656

Source: TheInsight Partners Analysis

Among all the infectious diseases, SARS-CoV-2 was all time high during 2020 to 2022 period where other uptake of vaccines including Dengue, Chickenpox, Tuberculosis, and others were low. However, SARS-CoV-2 vaccines uptake was all time high due to rising cases globally. According to the Public Health England report published in 2021, 12-month UK coverage for DTaP/IPV/Hib/HepB3 vaccination increased by 0.1% to 92.2% and Rotavirus by 0.3% to 90.6%. However, MenB2 decreased by 0.1, accounting for 92.3% compared to the previous year. Also, the NHS England report reveals that, in December 2022, a total of 88.9 of all adult care home residents had been vaccinated with a COVID-19 booster dose. Therefore, rising prevalence of infectious diseases, demand for vaccination is high resulting in overall market growth for the forecast period 2022-2030.

Type-Based Insights

Based on type, the vaccines market is segmented as live attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit & conjugate vaccines, and others. The live attenuated vaccines segment held the largest market share in 2022. Live attenuated vaccines are very effective vaccines used in the prevention of a variety of diseases, including influenza, chickenpox, measles, polio, and tuberculosis. As per the World Health Organization (WHO) report, there are around a billion cases of seasonal influenza, including 5 million cases of severe illness. Also, it causes around 290,000 to 650,000 respiratory deaths annually. Therefore, live-attenuated influenza vaccine (LAIV) proves advantageous to combat the infection among the population. For example, LAIV can provide upto 90% protection among adults under 65 years of age and upto 40% of adults over 65. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Based on application, the vaccines market is segregated into Human Papillomavirus (HPV), cancer, MMR, DPT, and others. The HPV segment held the largest market share in 2022. According to the WHO report, HPV is highly prevalent among women in Sub-Saharan Africa (24%), followed by Latin America and the Caribbean (16%), Eastern Europe (14%), and South-East Asia (14%). Also, 625,600 women and 694,000 men have HPV-related cancer annually globally. Also, in 2020, cervical cancer accounted for 93% of HPV-related cancers among women. Therefore, there is a high demand for HPV vaccines among the population due to rising prevalent cases, as these vaccines protect against genital warts and most cases of cervical cancer. Also, HPV vaccines are highly approved by the US Food and Drug Administration (USFDA). "GARDASIL 9" is one such example of an HPV vaccine approved by the US FDA. The aforementioned factors are responsible for influential segment growth for the forecast period 2022-2030.

Route of Administration-Based Insights

In terms of route of administration, the vaccines market is categorized as oral, nasal, and injectable. The injectable segment held a larger share of the market in 2022. The most common route of vaccine administration is through the injectable route, as administering a vaccine through a subcutaneous or intradermal route may cause local irritation, skin discoloration, inflammation, and many more.

Further, the CDC report reveals that DTaP, DT, HepA, HepB, Hib, HPV, IIV4, RIV4, ccIIV4, IPV*†, MenACWY, MenB, MMR‡ , PCV13, PPSV23*†, RZV, Td, Tdap, TT, VAR† are common vaccines administered through the injectable route of administration. Varied vaccines administered through injectable routes act as a standalone factor responsible for influential segment growth for the forecast period 2022-2030.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Vaccines Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Vaccines Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Vaccines Market - Global Market Analysis

6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2030

7. Vaccines Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Live Attenuated Vaccines
7.3 Inactivated Vaccines
7.4 Toxoid Vaccines
7.5 Subunit and Conjugate Vaccines
7.6 Others

8. Vaccines Market - Revenue Analysis (USD Million) - By Technology, 2020-2030

8.1 Overview
8.2 Recombinant Vaccines
8.3 mRNA Vaccines
8.4 Cell-Based Vaccines
8.5 Virus-Like Particles (VLPs)
8.6 Others

9. Vaccines Market - Revenue Analysis (USD Million) - By Application, 2020-2030

9.1 Overview
9.2 Human Papillomavirus (HPV)
9.3 Cancer
9.4 Measles, Mumps, Rubella (MMR)
9.5 Diptheria, Pertusis, Tetanus (DPT)
9.6 Others

10. Vaccines Market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2030

10.1 Overview
10.2 Oral
10.3 Injectable
10.4 Nasal

11. Vaccines Market - Revenue Analysis (USD Million) - By Age, 2020-2030

11.1 Overview
11.2 Pediatric
11.3 Adult

12. Vaccines Market - Revenue Analysis (USD Million) - By End User, 2020-2030

12.1 Overview
12.2 Healthcare Facilities (HCF)
12.3 Vaccination Centers and Programs
12.4 Others

13. Vaccines Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

13.1 North America
- 13.1.1 North America Vaccines Market Overview
- 13.1.2 North America Vaccines Market Revenue and Forecasts to 2030
- 13.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Type
- 13.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
- 13.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Application
- 13.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
- 13.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Age
- 13.1.8 North America Vaccines Market Revenue and Forecasts and Analysis - By End User
- 13.1.9 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
  - 13.1.9.1 United States Vaccines Market
    - 13.1.9.1.1 United States Vaccines Market, by Type
    - 13.1.9.1.2 United States Vaccines Market, by Technology
    - 13.1.9.1.3 United States Vaccines Market, by Application
    - 13.1.9.1.4 United States Vaccines Market, by Route of Administration
    - 13.1.9.1.5 United States Vaccines Market, by Age
    - 13.1.9.1.6 United States Vaccines Market, by End User
  - 13.1.9.2 Canada Vaccines Market
    - 13.1.9.2.1 Canada Vaccines Market, by Type
    - 13.1.9.2.2 Canada Vaccines Market, by Technology
    - 13.1.9.2.3 Canada Vaccines Market, by Application
    - 13.1.9.2.4 Canada Vaccines Market, by Route of Administration
    - 13.1.9.2.5 Canada Vaccines Market, by Age
    - 13.1.9.2.6 Canada Vaccines Market, by End User
  - 13.1.9.3 Mexico Vaccines Market
    - 13.1.9.3.1 Mexico Vaccines Market, by Type
    - 13.1.9.3.2 Mexico Vaccines Market, by Technology
    - 13.1.9.3.3 Mexico Vaccines Market, by Application
    - 13.1.9.3.4 Mexico Vaccines Market, by Route of Administration
    - 13.1.9.3.5 Mexico Vaccines Market, by Age
    - 13.1.9.3.6 Mexico Vaccines Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

13.2 Europe
- 13.2.1 Germany
- 13.2.2 France
- 13.2.3 Italy
- 13.2.4 Spain
- 13.2.5 United Kingdom
- 13.2.6 Rest of Europe
13.3 Asia-Pacific
- 13.3.1 Australia
- 13.3.2 China
- 13.3.3 India
- 13.3.4 Japan
- 13.3.5 South Korea
- 13.3.6 Rest of Asia-Pacific
13.4 Middle East and Africa
- 13.4.1 South Africa
- 13.4.2 Saudi Arabia
- 13.4.3 U.A.E
- 13.4.4 Rest of Middle East and Africa
13.5 South and Central America
- 13.5.1 Brazil
- 13.5.2 Argentina
- 13.5.3 Rest of South and Central America

14. Pre and Post Covid-19 Impact

15. Industry Landscape

15.1 Mergers and Acquisitions
15.2 Agreements, Collaborations, Joint Ventures
15.3 New Product Launches
15.4 Expansions and Other Strategic Developments

16. Competitive Landscape

16.1 Heat Map Analysis by Key Players
16.2 Company Positioning and Concentration

17. Vaccines Market - Key Company Profiles

17.1 GSK
- 17.1.1 Key Facts
- 17.1.2 Business Description
- 17.1.3 Products and Services
- 17.1.4 Financial Overview
- 17.1.5 SWOT Analysis
- 17.1.6 Key Developments

Note - Similar information would be provided for below list of companies